Are Tresiba Reviews Telling the Full Story? An Honest Audit

Tresiba at a glance:

• Drug class: Ultra-long-acting basal insulin analog
• Manufacturer: Novo Nordisk
• FDA approved: 2015
• Route: subcutaneous injection (FlexTouch pen)
• Typical frequency: once daily; flexible timing
• Half-life: ~25 hours (duration of action >42 hours)
• Cash price (US): ~$420–$480/month list; $35/month cap for Medicare beneficiaries

Online reviews are a flawed source. They overrepresent quitters and dramatic stories, and they underrepresent quiet long-term satisfaction. Read with that in mind, Tresiba reviews still tell you something useful.

What Users Praise

Across patient communities, the most consistent positive reports about Tresiba:

• The intended effect works. Users who reach maintenance dose and stay on it generally report meaningful change.
• Reduced food noise. A specific phrase users return to repeatedly — the cognitive load of food planning drops.
• Manageable routine. once daily; flexible timing dosing fits into ordinary life.

What Users Complain About

The complaint clusters are equally consistent:

• Side effects during titration. Most prominent in the first 4-8 weeks; usually improve at steady dose.
• Cost. ~$420–$480/month list; $35/month cap for Medicare beneficiaries is a meaningful barrier for many users without insurance coverage.
• Supply / availability. Supply consistency is variable.
• Plateau or response variability. Not everyone gets the trial-average response.

Patterns of Discontinuation

The most common reasons users report stopping Tresiba:

1. Cost or coverage change — accounts for the largest share of discontinuations
2. Side effects that don't improve at steady dose — minority of users
3. Reaching a target and choosing to taper — usually with mixed results long-term
4. Switching to a different agent — often based on prescriber recommendation

How to Read User Reviews

A few caveats worth keeping in mind when reading reviews of Tresiba:

• People who quit are overrepresented in negative reviews; long-term satisfied users post less
• Side-effect descriptions are often most prominent during the first weeks of titration
• Cost complaints reflect insurance and program eligibility — your situation may differ
• "Did it work?" is often answered before the maintenance dose is reached

What the Trials Add

Trial data cuts through some of the noise. DEVOTE (Marso 2017, NEJM) — non-inferior cardiovascular safety vs glargine; 40% lower nocturnal severe hypoglycemia. Comparable A1c reduction to glargine with significantly lower rates of nocturnal hypoglycemia (DEVOTE).

For deeper trial detail, see our Tresiba results page.

Comparing to Alternatives

When users compare Tresiba to alternatives, the head-to-head reviews tend to favor agents with better-characterized clinical evidence. Lantus (glargine), Levemir (detemir), and Toujeo are alternative basal insulins.

Bottom Line

Don't let online reviews talk you out of Tresiba (or into it). They capture real experience but with serious selection bias.

Frequently Asked Questions

Related Reading

• Tresiba Explained: How It Works and Who It's For
• Tresiba Side Effects in 2026: Real Reports, Real Solutions
• Real Tresiba Results: What 6 and 12 Months Actually Look Like
• Tresiba Cost in 2026: What You'll Actually Pay (Real Numbers)
• Is Lantus Right for You? An Evidence-Based Breakdown
• What Is Humalog? Everything You Should Know Before Starting

Sources

• American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care 2024;47(Suppl 1).
• Heise T et al. Insulin Pharmacokinetics and Pharmacodynamics. Diabetes Obes Metab 2017;19:3.

User reports are anecdotal and don't substitute for trial data or clinical guidance.